FA Community Petition
Food and Drug Administration and Reata Pharmaceuticals: Allow Individuals with Friedreich Ataxia Access to Omaveloxolone
The Friedreich’s Ataxia Research Alliance (FARA), with the support of 74,070 Friedreich’s Ataxia (FA) community members, 51 expert clinicians and 13 advocacy-organization partners submitted this petition requesting that Reata submit a New Drug Application (NDA) on an urgent basis and FDA consider approval of this NDA for omaveloxolone (omav) in Friedreich Ataxia (FA) based on the existing evidence from clinical trials.
